Xiamen Amoytop Biotech Co. Ltd.

Xiamen Amoytop Biotech Co. reported a significant performance increase on April 1, 2026, contrasting with broader market trends. The company has achieved 18 consecutive quarters of positive results, with record net sales and operating profit. Despite recent fluctuations, its profits have risen substantially over the past year.

Xiamen Amoytop Biotech Co. faced a decline in stock performance, with notable decreases over the past week and month. Despite these challenges, the company has consistently reported positive results for 18 quarters, showcasing strong operational metrics and a solid long-term growth trajectory.

Xiamen Amoytop Biotech Co. saw a significant stock decline today, contrasting with the broader market's performance. Despite recent downturns, the company has reported positive results for 18 consecutive quarters, with strong financial metrics, including a market capitalization of CNY 29,448 million and record net sales.

Xiamen Amoytop Biotech Co. has shown strong operational performance, reporting record net sales and operating profit over the past 18 quarters. Despite a challenging year, the company maintains a significant market presence with a robust market capitalization and favorable financial metrics, reflecting resilience in the biotechnology sector.